Stomach Cancer

Gene Activity Predicts Patient Response to Inhibitor Treatment for Stomach Cancer

By

Measurements of copies of a single gene circulating in the bloodstream allowed scientists to identify patients with stomach cancer who were most likely to respond to treatment.

Eradicating H. pylori may reduce stomach cancer risk

Eradicating H. pylori may reduce stomach cancer risk

The heliobacter pylori bacterium is the main cause of stomach ulcers, and it also a known risk factor for non-cardia gastric cancer.

Botox may be safe and effective for the treatment of gastric cancer

Botox may be safe and effective for the treatment of gastric cancer

Researchers found that the vagal nerve contributes to the growth of gastric tumors through the release of a neurotransmitter.

Genomic analysis clarifies subtypes of gastric cancer

By

In a massive effort to catalog the molecular causes of stomach cancer, scientists have identified four subtypes of tumors based on shared mutations and other molecular abnormalities. They say the new classification promises to advance clinical research to develop improved therapies for the third-leading cancer killer worldwide.

Cyramza approved by FDA for stomach cancer

Cyramza approved by FDA for stomach cancer

Cyramza (ramucirumab) has been approved by the U.S. Food and Drug Administration to treat cancer of the stomach.

Existing medicines promising for stomach and bowel cancer

By

Stomach and bowel cancer—two of the most common cancers worldwide—could be treated with a class of medicines that are currently used to treat a blood disorder, according to new research.

Metastatic Cancer (Fact Sheet)

This fact sheet reviews common sites of cancer metastasis, methods of spread, treatment, and additional details.

Hodgkin treatment raises risk for stomach cancer

By

Survivors of Hodgkin lymphoma who received subdiaphragmatic radiotherapy had dose-dependent increased risk for stomach cancer, researchers discovered.

Three subtypes of gastric cancer suggest different treatments

By

Stomach cancer, one of the leading causes of cancer death worldwide, actually falls into three broad subtypes that respond differently to currently available therapies, according to new research.

Higher risk of esophageal, stomach cancer with AIDS

Higher risk of esophageal, stomach cancer with AIDS

Non-Hodgkin lymphoma rates down but carcinoma rates fairly constant from 1980 to 2007.

Somatic mutations in two genes ID'd in stomach cancer

Somatic mutations in two genes ID'd in stomach cancer

Mutations were seen in FAT4 and ARID1A, involved in cell adhesion and chromatin remodeling.

Lung, pancreas only major cancers projected to have higher mortality in Europe in 2012

With the exception of lung cancer in women and pancreatic cancer, mortality from major cancers is expected to decline in the European Union in 2012.

AIDS raises risk for stomach and esophageal malignancies

A large study showed that people with AIDS are 6.9-fold more likely than the general population to develop stomach malignancies and 2.7 times more likely to have esophageal malignancies.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs